Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHCO vs SIBN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SIBN Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

SIBN Overall Winner 6-Pillar Tally: AHCO 3 – 3 SIBN Matrix Metrics: AHCO 4 – 6 SIBN

As of Nov 20, 2026, SI-BONE, Inc. (SIBN) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas SIBN carries 53.5/100 (HOLD) at $23.73 (N/M Forward P/E, -7.6% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHCO vs SIBN
AHCO NASDAQ
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32
SIBN NASDAQ Head-to-Head Winner
SI-BONE, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$23.73
-0.08% 1D
Market Cap $1.1B
TTM Revenue $221M
Forward P/E N/M
Beta / 30D Vol 0.65β · 74% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 45.0 Fund 57.0 Flow 72.0 Mom 56.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.9% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $23.32 · SMA50: $20.88

6-Pillar Scorecard Institutional Category Breakdown (AHCO 3 – 3 SIBN)

Columns: Metric · AHCO · SIBN
1. Valuation Multiples AHCO
Forward P/E 7.8x N/M
Trailing P/E 7.8x N/M
PEG Ratio N/M N/M
EV / Revenue 0.9x 4.9x
2. Growth & Scale SIBN
Revenue Growth (YoY) +10.9% +14.5%
Earnings Growth (YoY) +6.7% +0.0%
TTM Revenue (USD) $3.44B $221M
Market Cap $989.8M $1.1B
3. Profitability & Quality SIBN
Gross Margin 18.2% 79.4%
Operating Margin 3.8% -7.6%
Net Profit Margin -11.8% -6.2%
Return on Equity (ROE) -28.4% -7.7%
4. Balance Sheet & Cash Flow AHCO
Cash Generation (TTM) $82M -$4.2M
Cash Flow Margin 2.4% -1.9%
Net Cash / Leverage $1.97B Net Debt (1.67x D/E) $7.5M Net Debt (0.23x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SIBN
Options Structure Phase SURGE BREAKOUT
Current IV / %ile 66.9% (12th %ile) 149.2% (48th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat AHCO
OpEx & R&D Intensity 14.4% of Rev ($495M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHCO (4) vs SIBN (6)
Institutional Metric AHCO SIBN Criterion Row Edge
Market Capitalization
Scale
$989.8M $1.1B Larger Scale SIBN
Trailing P/E Ratio
Valuation
7.8x N/M Lower Multiple AHCO
Forward P/E Ratio
Valuation
7.8x N/M Lower Multiple AHCO
Revenue Growth (YoY)
Growth
+10.9% +14.5% Higher Growth SIBN
Operating Margin (TTM)
Profitability
3.8% -7.6% Higher Margin AHCO
Net Profit Margin
Profitability
-11.8% -6.2% Higher Margin SIBN
Return on Equity (ROE)
Capital Efficiency
-28.4% -7.7% Higher ROE SIBN
52-Week Range Position
Momentum
24% ($5–$13) 85% ($11–$26) Stronger Trend SIBN
Beta / 30D Volatility
Risk Regime
0.17β · 67% Vol 0.65β · 74% Vol Lower Realized Risk AHCO
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 53.5 / 100 (HOLD) Higher Composite SIBN
Trailing 12M Revenue (USD)
Operating Scale
$3.44B $221M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.2% 79.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$82M ($1.97B Net Debt (1.67x D/E)) -$4.2M ($7.5M Net Debt (0.23x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHCO +6.63 pp
AHCO: +16.69% · SIBN: +10.06%
3M Horizon AHCO +6.01 pp
AHCO: +27.89% · SIBN: +21.88%
6M Horizon SIBN +92.75 pp
AHCO: -31.1% · SIBN: +61.65%
1Y Horizon SIBN +48.46 pp
AHCO: -20.88% · SIBN: +27.58%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AHCO Revenue SIBN Revenue AHCO Op. Margin SIBN Op. Margin Margin Leader
FY2018 $350M $60M 9.0% -21.6% AHCO
FY2019 $530M $70M 5.5% -53.5% AHCO
FY2020 $1.06B $70M 6.8% -52.6% AHCO
FY2021 $2.45B $90M 9.2% -57.3% AHCO
FY2022 $2.97B $110M 6.4% -56.0% AHCO
FY2023 $3.20B $140M -18.7% -33.8% AHCO
FY2024 $3.26B $170M 8.1% -21.1% AHCO
FY2025 $3.24B $200M 2.8% -11.1% AHCO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SIBN BREAKOUT
78d in phase · OBV DISTRIBUTION
Current IV 149.2%
IV Percentile 48th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIBN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published
SIBN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.1B market capitalization and -7.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AHCO vs SIBN Key Questions & Quantitative Answers

As of Nov 20, 2026, SI-BONE, Inc. (SIBN) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas SIBN carries 53.5/100 (HOLD) at $23.73 (N/M Forward P/E, -7.6% operating margin). Technically, AHCO sits in a Markup phase (RSI 57.1, SURGE options structure) and SIBN sits in a Markup phase (RSI 57.6, BREAKOUT options structure).

SIBN leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with SIBN at +14.5% YoY revenue growth and +0.0% YoY earnings growth on $221M TTM revenue (79.4% gross margin, -7.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while SIBN shifted +233.3%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SIBN.

AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas SIBN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (-1.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus SIBN (-7.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, SIBN carries 149.2% implied volatility (48th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (0.65β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.